Charcot-Marie-Tooth Disease (Hereditary Neuropathy)

Charcot-Marie-Tooth disease (CMT) is the most common inherited neuromuscular disorder, affecting approximately 1 in 2,500 people worldwide. It is a group of hereditary peripheral neuropathies — not a single disease — caused by mutations in more than 100 different genes that encode proteins essential for the structure and function of peripheral nerves. The name comes from the three physicians who first described it in 1886: Jean-Martin Charcot, Pierre Marie, and Howard Henry Tooth. CMT causes slowly progressive muscle weakness and sensory loss, primarily in the lower legs and feet first, then the hands. While CMT is not life-threatening and does not affect life expectancy, it can cause significant disability and requires long-term management by a team of specialists. There is currently no disease-modifying treatment for most CMT types, though several promising gene therapy trials are underway.

CMT Types and Genetics

CMT is classified into types based on the underlying mechanism of nerve damage and the causative gene. CMT1 (demyelinating) is the most common — particularly CMT1A, caused by a duplication of the PMP22 gene on chromosome 17p11.2. CMT1A is inherited in an autosomal dominant pattern, meaning a child of an affected parent has a 50% chance of inheriting the mutation. PMP22 encodes peripheral myelin protein 22, and extra copies of this gene disrupt myelin formation and stability, leading to slow nerve conduction.

CMT2 (axonal) involves damage to the nerve axon rather than the myelin sheath. Nerve conduction is less slowed than in CMT1, but amplitude is reduced, reflecting axon loss. MFN2 mutations are the most common cause of CMT2. CMTX (X-linked) is caused by mutations in the GJB1 gene (Connexin-32) and affects males more severely than females. There are currently more than 100 genes identified as causing CMT or CMT-like hereditary neuropathies, and genetic testing panels continue to expand.

Genetic counseling is an important part of CMT management — particularly for patients of reproductive age who want to understand their risk of passing the condition to children and for newly diagnosed patients trying to confirm diagnosis and understand inheritance patterns.

Diagnosis

Diagnosis begins with a careful family history — CMT often affects multiple generations, though symptom severity varies. Nerve conduction studies (NCS) are essential: in demyelinating CMT (type 1), median nerve conduction velocity is markedly slowed (typically below 38 m/s); in axonal CMT (type 2), velocity is relatively preserved but amplitude is reduced. The NCS pattern combined with family history guides the initial classification.

Genetic testing is the definitive diagnostic tool and is increasingly available through commercial panels that test dozens to hundreds of CMT-associated genes simultaneously. The most cost-effective initial approach is typically to test for PMP22 duplication/deletion (the most common cause) first, then expand to panel testing if PMP22 is negative. Genetic testing identifies the specific mutation, confirms diagnosis, informs prognosis, guides genetic counseling, and is essential for participation in upcoming clinical trials.

Neuromuscular specialists with CMT expertise are the optimal physicians for diagnosis and ongoing management — general neurologists may have limited experience with the nuances of CMT genetics and the broader hereditary neuropathy spectrum. The CMT Association (CMTA) maintains a Certified CMT Center network of specialized clinics.

Management and Treatment

There is currently no FDA-approved disease-modifying therapy for most CMT types, though this is an active area of research. PXT3003 (a combination of baclofen, naltrexone, and sorbitol) completed phase III trials for CMT1A and showed modest benefit in some outcome measures; its regulatory status is evolving. Gene therapy approaches targeting PMP22 overexpression in CMT1A have entered early-phase clinical trials.

Management focuses on maintaining function and quality of life. Physical therapy and occupational therapy are cornerstones — strengthening exercises that target unaffected muscle groups to compensate for weak ones, gait training, and balance work can significantly reduce fall risk and improve function over time. Ankle-foot orthoses (AFOs) are frequently prescribed for foot drop and ankle instability. Correctly fitted footwear and custom orthotics address the high arch deformity and toe contractures.

Pain management is less prominent in CMT than in acquired neuropathies, as sensory loss rather than neuropathic pain is the primary complaint for many patients. Some patients do experience significant neuropathic pain, which is managed similarly to other peripheral neuropathies. Patients should avoid neurotoxic agents — certain medications (vincristine, high-dose B6, colchicine) can accelerate CMT-related nerve damage and should be avoided when alternative treatments are available.

Related Treatments

Frequently Asked Questions

Is Charcot-Marie-Tooth disease fatal?

No. CMT does not affect life expectancy. It primarily affects the peripheral nervous system — the motor and sensory nerves of the limbs — and does not involve the brain, spinal cord, or vital organs directly. While it can cause significant functional disability and reduce quality of life, patients live full lifespans. In rare, severe early-onset forms (CMT4), more significant disability may occur, but fatality from CMT itself is not expected.

Can children inherit CMT if only one parent has it?

The inheritance risk depends on the CMT type. For autosomal dominant CMT (including CMT1A, the most common form), each child of an affected parent has a 50% chance of inheriting the causative mutation. For autosomal recessive CMT (CMT4 types), both parents must carry a mutation — their children have a 25% chance of being affected. For CMTX, daughters of affected fathers are carriers (but may be mildly affected), while sons do not inherit from their father’s X-linked mutation. Genetic counseling should be part of every CMT family’s care plan.

What exercise is best for CMT patients?

Low-impact aerobic exercise that does not overly stress weakened muscles — swimming, cycling, and aquatic therapy are commonly recommended. Strength training targeted at muscles less affected by CMT (hip stabilizers, proximal leg muscles) can meaningfully improve function. Aggressive resistance training of already weak muscle groups should be approached cautiously to avoid overwork injury. A physical therapist experienced with neuromuscular diseases should guide an individualized exercise program.

Are there clinical trials for CMT?

Yes — this is an active research area. The CMT Association (CMTA) at cmtausa.org maintains an updated list of open clinical trials. For CMT1A specifically, several gene therapy and drug trials are at various stages. Patients interested in trial participation should discuss eligibility with a neuromuscular specialist and review clinicaltrials.gov using search term ‘Charcot-Marie-Tooth’ to find currently enrolling studies.